Patent · US Active

Morphine formulations

US10213424B2 · kind B2 · utility

1Cited by

54References

46Claims

0Family size

Assignee

Fresenius Kabi Deutschland GmbH · DE

Inventors

Alain Cuine · Saint-Jean-de-Braye, FR
Didier Hoarau · Le Pont-de-Claix, FR
Pauline ROMAIN · Yssingeaux, FR

Key dates

Filing date	Oct 20, 2015
Grant date	Feb 26, 2019
Priority date	—
Expiry date	Oct 20, 2035

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P25/04
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided herein, generally, are pharmaceutical formulations, e.g., injectable pharmaceutical formulations with improved stability, comprising morphine sulfate or a hydrate thereof, and methods of producing and using the same. Also provided herein are kits comprising the formulations, e.g., injectable morphine formulations.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.